The National Institute of Mental Health (NIMH) has issued an inaccurate, obfuscating, and misleading statement ON April 23, 2004 — Antidepressant Medications for Children: Information for Parents and Caregivers — that continues to encourage the use of antidepressants for children: “Many times, psychotherapy accompanied by an early follow- up appointment may help to establish the persistence of depression before a decision is made to try antidepressant medications.” This statement appears to demonstrate the inordinate influence of Big Pharma on NIMH. http://www.nimh.nih.gov/press/StmntAntidepmeds.cfm
VIOXX – Merck–MEDCO – a case study Wed, 13 Oct 2004 Vioxx: A case study in how a lethal drug is marketed and dispensed – without MINIMAL safeguards to protect people’s lives. Merck marketed and sold billions of dollars worth of Vioxx . . . Continue reading →
Associated Press: More Details about FDA Warning Strattera Associated with Suicide Thu, 29 Sep 2005 On April 26, 2004, we wrote: “The Alliance for Human Research Protection is concerned that children who are prescribed the failed antidepressant, Strattera, may be exposed to . . . Continue reading →
Tell the Truth About Antidepressants On Drug Labels & in Medical Journals Thu, 16 Sep 2004 An April, 2004 editorial in the New York Times noted: “What seems most astonishing is the skimpy evidence that these drugs work at all in most . . . Continue reading →
A request for comment about NIH proposed new research misconduct rule
See Fed Register:
The new rule, I believe is meant to protect research institutions from the effective sting of a knowledgeable whistle blower.
The new rule would redefine whistle-blower as “complainant” and would limit the role of the complainant. Under the old rule, the whistle-blower participated in the process helping investigators by leading them to the evidence, etc.